RE:Yeast capsules with avenanthramide - Canada/China Joint Lab"Moreover, the loading of AVN-C induced high hydrophobicity inside the yeast capsules, which helped to protect AVN-C against degradation and release AVN-C in a slow and sustained manner in the simulated gastrointestinal tract. The YCW capsules have potential as controlled delivery system for AVN-C, which could be further used as a nutraceutical and added to functional foods."
CZO previously talked about impregnating avenanthramide into its newer generation PGX carriers with promising results. Could we have PGX-YBG/Avenanthramide? Could we have a slow-release formulation of avenanthramide with the enhanced anti-inflammatory activities of PGX-YBG and avenanthramide potentially working together synergistically?